|drug2825||Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Wiki||0.50|
There is one clinical trial.
There is no evidence that the Bacille Calmette-Guérin vaccine (BCG) protects people against infection with COVID-19 virus. Two clinical trials addressing this question are underway, and WHO will evaluate the evidence when it is available. In the absence of evidence, WHO does not recommend BCG vaccination for the prevention of COVID-19. WHO continues to recommend neonatal BCG vaccination in countries or settings with a high incidence of tuberculosis. There is experimental evidence from both animal and human studies that the BCG vaccine has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance is unknown
Description: severity of COVID-19 pneumoniaMeasure: Pneumonia severity index Time: 2 weeks
Description: severe pneumonia indicating invasive or non invasive mechanical ventilationMeasure: Need for ICU admission Time: 2 weeks
Description: number of days to cure from COVID-19 diseaseMeasure: COVID -19 test conversion Time: 2 weeks
Description: frequency of fatalitiesMeasure: Mortality Time: 2 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports